Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations

Osimertinib, a mutant-specific third generation EGFR TKI, is emerging as the preferred first-line therapy for EGFR mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib in transgenic mouse models of EGFR(L858R)-induced lung adenocarcinoma a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Starrett, Jacqueline H., Guernet, Alexis A., Cuomo, Maria Emanuela, Poels, Kamrine E., van Alderwerelt van Rosenburgh, Iris K., Nagelberg, Amy, Farnsworth, Dylan, Price, Kristin S., Khan, Hina, Ashtekar, Kumar D., Gaefele, Mmaserame, Ayeni, Deborah, Stewart, Tyler F., Kuhlmann, Alexandra, Kaech, Susan, Unni, Arun M., Homer, Robert, Lockwood, William W., Michor, Franziska, Goldberg, Sarah B., Lemmon, Mark A., Smith, Paul D., Cross, Darren A., Politi, Katerina
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392201/
https://ncbi.nlm.nih.gov/pubmed/32193290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3819
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados